These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37356253)

  • 1. Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines.
    Binderup A; Galli A; Fossat N; Fernandez-Antunez C; Mikkelsen LS; Rivera-Rangel LR; Scheel TKH; Fahnøe U; Bukh J; Ramirez S
    Virology; 2023 Aug; 585():179-185. PubMed ID: 37356253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice.
    Eyer L; Nougairède A; Uhlířová M; Driouich JS; Zouharová D; Valdés JJ; Haviernik J; Gould EA; De Clercq E; de Lamballerie X; Ruzek D
    J Virol; 2019 Aug; 93(16):. PubMed ID: 31142664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure.
    Mendes ÉA; Pilger DRB; Santos Nastri ACS; Malta FM; Pascoalino BDS; Carneiro D'Albuquerque LA; Balan A; Freitas LHG; Durigon EL; Carrilho FJ; Rebello Pinho JR
    Ann Hepatol; 2019; 18(6):816-824. PubMed ID: 31594756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.
    Sandberg JT; Löfling M; Varnaitė R; Emgård J; Al-Tawil N; Lindquist L; Gredmark-Russ S; Klingström J; Loré K; Blom K; Ljunggren HG
    PLoS Negl Trop Dis; 2023 Feb; 17(2):e0010616. PubMed ID: 36758067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-[
    Sedenkova KN; Sazonov AS; Vasilenko DA; Andriasov KS; Eremenko MG; Grishin YK; Khvatov EV; Goryashchenko AS; Uvarova VI; Osolodkin DI; Ishmukhametov AA; Averina EB
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Investigation of oncolytic potential of vaccine strains of yellow fever and tick-borne encephalitis viruses against glioblastoma and pancreatic carcinoma cell lines].
    Nazarenko AS; Biryukova YK; Orlova EO; Trachuk KN; Ivanova AL; Belyakova AV; Pestov NB; Vorovitch MF; Ishmukhametov AA; Kolyasnikova NM
    Vopr Virusol; 2023 Dec; 68(6):536-548. PubMed ID: 38156569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo.
    de Freitas CS; Higa LM; Sacramento CQ; Ferreira AC; Reis PA; Delvecchio R; Monteiro FL; Barbosa-Lima G; James Westgarth H; Vieira YR; Mattos M; Rocha N; Hoelz LVB; Leme RPP; Bastos MM; Rodrigues GOL; Lopes CEM; Queiroz-Junior CM; Lima CX; Costa VV; Teixeira MM; Bozza FA; Bozza PT; Boechat N; Tanuri A; Souza TML
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007072. PubMed ID: 30699122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydroquinazoline N-oxide derivatives inhibit reproduction of tick-borne and mosquito-borne flaviviruses.
    Sedenkova KN; Uvarova VI; Nazarova AA; Peisikova AV; Khvatov EV; Sukhorukov MV; Frolenko VS; Goryashchenko AS; Kholodilov IS; Grishin YK; Rybakov VB; Makenov MT; Morozkin ES; Karan LS; Kozlovskaya LI; Ishmukhametov AA; Osolodkin DI; Averina EB
    Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300027. PubMed ID: 37138375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of recombinant tick-borne encephalitis virus expressing mCherry reporter protein: A new tool for high-throughput screening of antiviral compounds, and neutralizing antibody assays.
    Haviernik J; Eyer L; Yoshii K; Kobayashi S; Cerny J; Nougairède A; Driouich JS; Volf J; Palus M; de Lamballerie X; Gould EA; Ruzek D
    Antiviral Res; 2021 Jan; 185():104968. PubMed ID: 33157129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
    Ramirez S; Fernandez-Antunez C; Galli A; Underwood A; Pham LV; Ryberg LA; Feng S; Pedersen MS; Mikkelsen LS; Belouzard S; Dubuisson J; Sølund C; Weis N; Gottwein JM; Fahnøe U; Bukh J
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0009721. PubMed ID: 33903110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model System for the Formation of Tick-Borne Encephalitis Virus Replication Compartments without Viral RNA Replication.
    Yau WL; Nguyen-Dinh V; Larsson E; Lindqvist R; Överby AK; Lundmark R
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243132
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses.
    Eyer L; Zouharová D; Širmarová J; Fojtíková M; Štefánik M; Haviernik J; Nencka R; de Clercq E; Růžek D
    Antiviral Res; 2017 Jun; 142():63-67. PubMed ID: 28336346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus.
    Gao Z; Zhang L; Ma J; Jurado A; Hong SH; Guo JT; Rice CM; MacDonald MR; Chang J
    Antiviral Res; 2020 Oct; 182():104907. PubMed ID: 32798604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of chimera of yellow fever virus vaccine strain and Tick-Borne encephalitis virus.
    Kuznetsova N; Siniavin A; Butenko A; Larichev V; Kozlova A; Usachev E; Nikiforova M; Usacheva O; Shchetinin A; Pochtovyi A; Shidlovskaya E; Odintsova A; Belyaeva E; Voskoboinikov A; Bessonova A; Vasilchenko L; Karganova G; Zlobin V; Logunov D; Gushchin V; Gintsburg A
    PLoS One; 2023; 18(5):e0284823. PubMed ID: 37163522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus.
    Zandi K; Amblard F; Amichai S; Bassit L; Tao S; Jiang Y; Zhou L; Ollinger Russell O; Mengshetti S; Schinazi RF
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of IFITM Proteins in Tick-Borne Encephalitis Virus Infection.
    Chmielewska AM; Gómez-Herranz M; Gach P; Nekulova M; Bagnucka MA; Lipińska AD; Rychłowski M; Hoffmann W; Król E; Vojtesek B; Sloan RD; Bieńkowska-Szewczyk K; Hupp T; Ball K
    J Virol; 2022 Jan; 96(1):e0113021. PubMed ID: 34613785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody ratios against NS1 antigens of tick-borne encephalitis and West Nile viruses support differential flavivirus serology in dogs.
    Könenkamp L; Ziegler U; Naucke T; Groschup MH; Steffen I
    Transbound Emerg Dis; 2022 Sep; 69(5):e2789-e2799. PubMed ID: 35704505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines.
    Ruzek D; Avšič Županc T; Borde J; Chrdle A; Eyer L; Karganova G; Kholodilov I; Knap N; Kozlovskaya L; Matveev A; Miller AD; Osolodkin DI; Överby AK; Tikunova N; Tkachev S; Zajkowska J
    Antiviral Res; 2019 Apr; 164():23-51. PubMed ID: 30710567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Activity of Uridine Derivatives of 2-Deoxy Sugars against Tick-Borne Encephalitis Virus.
    Krol E; Wandzik I; Brzuska G; Eyer L; Růžek D; Szewczyk B
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30901934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-Cell Immunoglobulin and Mucin Domain 1 (TIM-1) Is a Functional Entry Factor for Tick-Borne Encephalitis Virus.
    Zhang X; Liang C; Wang H; Guo Z; Rong H; Pan J; Li W; Pei R; Chen X; Zhang Z; Zhang XE; Cui Z
    mBio; 2022 Feb; 13(1):e0286021. PubMed ID: 35073759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.